drugset / Trial / NCT04982900
Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities
Phase 2
Unknown
138 enrolled
Ruijin Hospital
First Affiliated Hospital of Zhejiang University · collabFujian Medical University Union Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabTang-Du Hospital · collabThe First Affiliated Hospital of Nanchang University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a multi-center, prospective, double-blind randomized controlled clinical trial. The purpose is to evaluate the efficacy and safety of EGFR-TKI on residual GGOs after surgery in patients with multiple primary lung cancers with ground glass nodules. This study is expected to prove that compared with placebo in the control group, EGFR-TKI can significantly reduce the residual GGOs lesions in patients with EGFR-positive multiple primary lung cancers with ground-glass opacity, and bring a higher objective response rate (ORR), thus provides new insights for treatment of these patients.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Firmonertinib | Small molecule | 80 mg | Oral |